Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Vaxil Bio Ltd VXLLF


Primary Symbol: V.VXL

Healthcare Biotechnology
Vaxil Bio Ltd. is a Canada-based biotechnology company. The Company is focused on a drug discovery and development platform based on Signal Peptides (SPs) which the Company deploys to fight infectious diseases and cancer. The Company’s most advanced product, ImMucin, a MUC1 SP-derived vaccine, completed a Phase I/II clinical trial in multiple myeloma. The Company also has a SP-based COVID-19 vaccine candidate and a SP-based tuberculosis vaccine / treatment candidate. In addition, The Company has mAb candidates for the treatment of oncology and infectious diseases to be used alone, and in combination with other treatments. It has also initiated a pre-clinical program for a drug delivery polymer that targets high affinity E-selectin (P-Esbp), which the Company licensed for development and commercialization from BGN Technologies. It exploits the properties of SP domains on crucial proteins to develop targeted therapies against cancer targets and infectious disease pathogens.


TSXV:VXL - Post by User

Vaxil Bio Ltd > Will be back at 0.07¢ very soon according to some analysts
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(15)
•••
Comment by abingo1on Oct 01, 2021 1:27am
223 Views
Post# 33951000

RE:Will be back at 0.07¢ very soon according to some analysts

RE:Will be back at 0.07¢ very soon according to some analysts
Traderstock101 wrote: The Basher and Pompous Day Traders took their profits and the shorts are starting to move towards the 0.07 ¢ very soon...


The news is all good!
Why should it Implode to 0.07 

In addition, Vaxil announces that it further strengthens its intellectual property assets regarding the treatment of tuberculosis by using SPs, since a patent will be issued in the U.S. (U.S. patent No. 11135277) on 5 October, 2021, titled: “Antigen specific multi epitope-based anti-infective vaccines”, that includes claims relating to various SP-based anti-tuberculosis vaccines.

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities